Companies: 10,795·Total market cap: $144.5T
Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc.

THRXNASDAQHealthcare
$4.07
+$0.01(+0.12%)
Market Cap$181498998
P/E Ratio
52W High$12.37
52W Low$2.05
Overview

Theseus Pharmaceuticals, Inc. (THRX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001745020 · THRX · NASDAQ · as of Jun 9, 2026

Filing snapshot

181
Total Filings
15-12G
Latest Form
2024-02-26
Most Recent
2021
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001745020 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2023-03-09
Fiscal Year End
Mar 9, 2023
Accession No.
0001558370-23-003251
Primary Document
thrx-20221231x10k.htm
Source: data.sec.gov · CIK 0001745020 · Accession 0001558370-23-003251

Latest Key Filings

10-QQuarterly Report
10-Q
2023-11-17
8-KCurrent Report
FORM 8-K
2024-02-14Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
15-12G15-12G
15-12G
2024-02-26
View
SC 13D/ASC 13D/A
AMENDMENT NO. 3
2024-02-16
View
EFFECTEFFECT
EFFECT
2024-02-15
View
S-8 POSS-8 POS
S-8 POS
2024-02-14
View
S-8 POSS-8 POS
S-8 POS
2024-02-14
View
POS AMPOS AM
POS AM
2024-02-14
View
8-KCurrent Report
FORM 8-K
2024-02-14
View
SC TO-T/ASC TO-T/A
FORM SC TO-T/A
2024-02-14
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2024-02-14
View
25-NSE25-NSE
25-NSE
2024-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
SC 13G/A
2024-02-13
View
CORRESPCORRESP
CORRESP
2024-02-07
View
SC 14D9/ASC 14D9/A
SC 14D9/A
2024-02-07
View
SC TO-T/ASC TO-T/A
FORM SC TO-T/A
2024-02-07
View
UPLOADUPLOAD
UPLOAD
2024-02-02
View
Showing 1–15 of 123 filingsForm 4 / 144 hidden· 181 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001745020  |  Exchange: NASDAQ · Healthcare

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) has submitted 181 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001745020, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Theseus Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Theseus Pharmaceuticals, Inc. 10-K was filed on 2023-03-09 for fiscal year ending 2023. Historical THRX 10-K annual reports are available from 2018 through 2023.

Investors researching Theseus Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

THRX SEC Filings · 8 questions

Theseus Pharmaceuticals, Inc. (THRX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 181 filings and access original documents at no cost. Theseus Pharmaceuticals, Inc.'s CIK is 0001745020.

THRX SEC filingsTheseus Pharmaceuticals, Inc. SEC documentsfind THRX 10-K